TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20512500

Group type: EXPERIMENTAL
Intervention: Sprint exercise (two 30‐s maximal efforts on a cycle ergometer)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Boxing (two 30‐s maximal punching efforts)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Violent video game (10 min of player vs. player combat)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inactive days (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 7
Study: 18207016

Group type: EXPERIMENTAL
Intervention: Modified-release prednisone tablet taken at bedtime, released with a delay of 4 hours after ingestion.
Number of subjects: 288

Group type: COMPARATOR
Intervention: Immediate-release prednisone tablet taken in the morning as an active comparator.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Modified-release prednisone
Number of subjects: 288

Group type: COMPARATOR
Intervention: Immediate-release prednisone
Number of subjects: 288
Study: 15688278

Group type: EXPERIMENTAL
Intervention: Recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine
Number of subjects: 5403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5403
Study: 12730120

Group type: EXPERIMENTAL
Intervention: Single or double autologous peripheral blood stem cell transplantation
Number of subjects: 74
Study: 10774461

Group type: EXPERIMENTAL
Intervention: Anti-TNF reagents (infliximab and etanercept)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 0
Study: 8853471

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 2059880

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 65
Study: 3993898

Group type: EXPERIMENTAL
Intervention: Vented patients (4.5 mm lateral drill hole 4 cm distal the tip of the prosthesis)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no venting)
Number of subjects: 26
Study: 29026977

Group type: EXPERIMENTAL
Intervention: PVP (PROCEED® Ventral Patch)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Mesh
Number of subjects: 352
Study: 26358166

Group type: EXPERIMENTAL
Intervention: Nut-enriched bread with 30g finely sliced hazelnuts
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nut-enriched bread with 30g semi-defatted hazelnut flour
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nut-enriched bread with 15g finely sliced hazelnuts and 15g semi-defatted hazelnut flour
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control nut-free bread
Number of subjects: 32
Study: 25192498

Group type: EXPERIMENTAL
Intervention: Dersalazine sodium 1200 mg/12 h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mesalazine 1200 mg/12 h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dersalazine sodium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 34
Study: 21793108

Group type: EXPERIMENTAL
Intervention: MFT + CBT-E (n=52)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CBT-E (n=43)
Number of subjects: 95
Study: 21524314

Group type: EXPERIMENTAL
Intervention: Moderately high protein diet (30% protein, 40% carbohydrate)
Number of subjects: 83

Group type: COMPARATOR
Intervention: High fiber, relatively high carbohydrate diet (50% carbohydrate, > 35 g total dietary fiber, 20% protein)
Number of subjects: 83
Study: 18377694

Group type: COMPARATOR
Intervention: No additional exercise (Nex)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (Mex; 1.5-2.0 MJ/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (Hex; 3.0-4.0 MJ/d)
Number of subjects: 12
Study: 17062305

Group type: EXPERIMENTAL
Intervention: Sustained-release glipizide (GSR) 10 mg PO QD
Number of subjects: 57

Group type: COMPARATOR
Intervention: Immediate-release glipizide (GIR) 5 mg PO BID
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sustained-release glipizide (GSR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Immediate-release glipizide (GIR)
Number of subjects: 57
Study: 12933344

Group type: EXPERIMENTAL
Intervention: 8-week exercise training
Number of subjects: 75
Study: 10880063

Group type: EXPERIMENTAL
Intervention: Pilot psychological intervention program for stress management techniques
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care preparation for child's BMT
Number of subjects: 22
Study: 8918625

Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate (10-100 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate (100 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate (10-40 mg)
Number of subjects: 18
Study: 1417433

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (alone or in combination with medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine hydrochloride pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined cognitive-pharmacotherapy
Number of subjects: 0
Study: 6399888

Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination tablet (40 mg frusemide and 5 mg amiloride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no diuretics)
Number of subjects: 12
Study: 30613127

Group type: EXPERIMENTAL
Intervention: Culturally tailored online human subjects curriculum
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard nationally used online curriculum
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Culturally tailored curriculum
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Culturally tailored research ethics curriculum
Number of subjects: 244
Study: 30982021

Group type: EXPERIMENTAL
Intervention: Jacobson progressive muscular relaxation (PMR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Relaxing music (control)
Number of subjects: 58
Study: 26686053

Group type: EXPERIMENTAL
Intervention: Thermafil (TF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cold Lateral Condensation (CLC)
Number of subjects: 112
Study: 24380874

Group type: EXPERIMENTAL
Intervention: Behavioural voice therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed treatment (after eight week assessment)
Number of subjects: 200
Study: 22581647

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy controls without osteopenia/osteoporosis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Postmenopausal women with osteoporosis
Number of subjects: 66
Study: 20384746

Group type: EXPERIMENTAL
Intervention: Tamoxifen tablets postoperatively according to a standard protocol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 17021589

Group type: EXPERIMENTAL
Intervention: SmartStep auditory biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 16061590

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg, once daily)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Fluticasone (100 microg, twice daily)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 994

Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 994
Study: 12153622

Group type: EXPERIMENTAL
Intervention: Metallic stent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plastic endoprosthesis
Number of subjects: 50
Study: 10196011

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 84

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 84
Study: 7768240

Group type: EXPERIMENTAL
Intervention: Gas mixture with reduced oxygen content (H; oxygen fraction in inspired gas 0.14)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air (N)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gas mixture with reduced oxygen content (H)
Number of subjects: 14
Study: 2180658

Group type: EXPERIMENTAL
Intervention: Tofu-based frozen dessert (TFD) containing high-fructose corn syrups
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dairy-based sucrose-sweetened ice cream (IC)
Number of subjects: 12
Study: 7418951

Group type: EXPERIMENTAL
Intervention: Biperiden hydrochloride (Akineton)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzhexol (Artane)
Number of subjects: 0
Study: 30813605

Group type: EXPERIMENTAL
Intervention: Nutri-Score information provided
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Nutri-Score information)
Number of subjects: 0
Study: 28609532

Group type: EXPERIMENTAL
Intervention: FAST examination
Number of subjects: 975

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 975
Study: 25863549

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 3812

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 3812
Study: 24090125

Group type: EXPERIMENTAL
Intervention: Diarrhea Pack (ORS, Zinc, water purification, improved hygiene and sanitation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 8
Study: 21854162

Group type: EXPERIMENTAL
Intervention: Bed-rest exercise and music (n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bed-rest and music (n = 5)
Number of subjects: 11
Study: 19957871

Group type: EXPERIMENTAL
Intervention: Pool-aquatic program in warm water (three weekly 60-min sessions for four months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pool-aquatic program in warm water
Number of subjects: 14
Study: 17067587

Group type: EXPERIMENTAL
Intervention: Forearm vasodilatation in response to endothelium-dependent dilators (acetylcholine/bradykinin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Forearm vasodilatation in response to endothelium-independent dilators (nitroprusside/verapamil)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vascular function in obese or lean women with PCOS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Androgen levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 24
Study: 12852237

Group type: EXPERIMENTAL
Intervention: Chemotherapy (drugs such as cyclophosphamide, 5-fluorouracil, and doxorubicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10709795

Group type: EXPERIMENTAL
Intervention: Gimme 5 intervention (curriculum, newsletters, videotapes, point-of-purchase education)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gimme 5 intervention
Number of subjects: 16
Study: 9327037

Group type: EXPERIMENTAL
Intervention: Filgrastim (r-metHuG-CSF) 75-600 micrograms day-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim (r-metHuG-CSF) 150-600 micrograms day-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim (r-metHuG-CSF)
Number of subjects: 30
Study: 8138869

Group type: EXPERIMENTAL
Intervention: Rehearsal-plus
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: General information
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 3733311

Group type: EXPERIMENTAL
Intervention: Eccentric exercise regimen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isometric exercise regimen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concentric exercise regimen
Number of subjects: 28
Study: 28941196

Group type: EXPERIMENTAL
Intervention: Vortioxetine (single rising doses)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vortioxetine (multiple doses)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vortioxetine (fed state)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 27383469

Group type: EXPERIMENTAL
Intervention: Self-paced exercise (not to exceed 76% maximum heart rate)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Prescribed moderate intensity exercise (64-76% maximum heart rate)
Number of subjects: 59
Study: 23975116

Group type: EXPERIMENTAL
Intervention: Positive mood manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-related stimuli
Number of subjects: 0
Study: 22277837

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 424

Group type: COMPARATOR
Intervention: Chemotherapy (standard docetaxel or pemetrexed regimens)
Number of subjects: 424
Study: 20729242

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide alone (150 mg/m²/day, 7/14‐day schedule)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus thalidomide (400 mg/day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus isotretinoin (100 mg/m²/day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus celecoxib (400 mg twice daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus thalidomide plus isotretinoin plus celecoxib
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall treatment (dose-dense temozolomide with cytostatic agents)
Number of subjects: 54
Study: 18362587

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 1000
Study: 15052242

Group type: EXPERIMENTAL
Intervention: Radionuclide perfusion testing
Number of subjects: 2951

Group type: EXPERIMENTAL
Intervention: Post-catheterization nuclear cohort
Number of subjects: 2951
Study: 11534926

Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment (IMI-IMI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Imipramine followed by placebo substitution (IMI-PBO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo maintenance treatment (PBO-PBO)
Number of subjects: 18
Study: 9040027

Group type: EXPERIMENTAL
Intervention: HCM patients with ASH and CD36 deficiency
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: DCM patients with CD36 deficiency
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pressure-overload hypertrophy patients with CD36 deficiency
Number of subjects: 47

Group type: COMPARATOR
Intervention: HCM patients without ASH
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Other HCM patients with ASH and CD36 deficiency
Number of subjects: 47
Study: 8572058

Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emissions (DPOEs) testing in elderly subjects
Number of subjects: 71
Study: 3065737

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 400 mg/kg body weight every 3 weeks for a year
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 84
Study: 29794557

Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg bid)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28760211

Group type: EXPERIMENTAL
Intervention: Intensive follow-up via telemonitoring using an implantable cardiac monitor (ICM) device
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 1600
Study: 26226287

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sleep Control
Number of subjects: 18
Study: 23532241

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily) for 12 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21462730

Group type: EXPERIMENTAL
Intervention: Morbidly obese adults
Number of subjects: 457

Group type: COMPARATOR
Intervention: General population
Number of subjects: 457
Study: 18433945

Group type: EXPERIMENTAL
Intervention: Glutamate ingestion (30 mg/kg BW)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control ingestion (1.25 ml/kg BW)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Glutamate ingestion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control ingestion
Number of subjects: 26
Study: 16784930

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 14501096

Group type: EXPERIMENTAL
Intervention: Multi-faceted injury prevention program (4 hours of individualized training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 10718783

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 8 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9361339

Group type: EXPERIMENTAL
Intervention: m‐chlorophenylpiperazine (mCPP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1530533

Group type: EXPERIMENTAL
Intervention: MATCOP
Number of subjects: 80

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 80
Study: 3886340

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg orally each morning)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Ranitidine (150 mg orally twice daily)
Number of subjects: 184
Study: 31041425

Group type: EXPERIMENTAL
Intervention: Hope intervention (3 sessions)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control intervention (EDU)
Number of subjects: 29
Study: 30107279

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Interpersonal exposure
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control
Number of subjects: 266
Study: 26459316

Group type: EXPERIMENTAL
Intervention: Preventure intervention
Number of subjects: 699
Study: 24238943

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acrylic IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HSM PMMA IOL
Number of subjects: 0
Study: 22057829

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 10 ppm followed by sildenafil 100 mg orally 30 minutes later
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sildenafil 100 mg orally followed by inhaled nitric oxide (iNO) 10 ppm 60 minutes later
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coadministration of iNO and sildenafil
Number of subjects: 20
Study: 19821509

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.2 mg/kg daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg daily (open-label phase)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Teduglutide (all doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 100
Study: 17432690

Group type: EXPERIMENTAL
Intervention: Compound Shiwei Tablet (CST)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Sanjin Tablet (ST)
Number of subjects: 459
Study: 15367305

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg as a single dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 27
Study: 11255905

Group type: EXPERIMENTAL
Intervention: Inclusion of an income question in the survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seeking consent to access medical records
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 0
Study: 9676354

Group type: EXPERIMENTAL
Intervention: New sustained release theophylline microcapsules (T1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New sustained release theophylline microcapsules (T2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pellet formulation (R)
Number of subjects: 0
Study: 8047519

Group type: EXPERIMENTAL
Intervention: Health education interventions
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Perceived self‐efficacy
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Salience and coherence of testing
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 501
Study: 2926492

Group type: EXPERIMENTAL
Intervention: Endoscopic evacuation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 100
Study: 30110020

Group type: EXPERIMENTAL
Intervention: Provider apologies in the electronic health record
Number of subjects: 100
Study: 29869903

Group type: EXPERIMENTAL
Intervention: Immunophenotypically aberrant MCL
Number of subjects: 158

Group type: COMPARATOR
Intervention: Immunophenotypically typical MCL
Number of subjects: 158
Study: 28644104

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Number of subjects: 625
Study: 26148133

Group type: EXPERIMENTAL
Intervention: Low-dose creatine supplementation (acute and chronic)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose creatine supplementation (acute and chronic)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study: 25098088

Group type: EXPERIMENTAL
Intervention: Single dose of injection Celfuroxime 1.5 gm at the time of induction of anaesthesia (Group A)
Number of subjects: 350

Group type: COMPARATOR
Intervention: No antibiotic (Group B)
Number of subjects: 350
Study: 20842041

Group type: EXPERIMENTAL
Intervention: i‐LMA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: GVL
Number of subjects: 121

Group type: COMPARATOR
Intervention: DL
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: i‐LMA vs GVL
Number of subjects: 121
Study: 19092349

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment (250 mg at consent, followed by 100 mg/h infusion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 100